All In Biotech

Drug Trial Radar · NCT03358576

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults

Last checked: Nov 19, 2026Latest source record: Dec 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 674 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

674

Actual

Start

Sep 18, 2018

Primary completion

Oct 2, 2019

Study completion Oct 2, 2019

Sponsor

Sponsor type
Industry
First posted
Nov 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin-metronidazole for treatment of complicated intra-abdominal infections in adults.

Conditions

  • Intra Abdominal Infections

Interventions

  • ErtapenemDrug

    Antibiotic for complicated intra-abdominal infection

  • Sulopenem-Etzadroxil/ProbenecidDrug

    Antibiotic for complicated intra-abdominal infection

  • CiprofloxacinDrug

    Antibiotic for complicated intra-abdominal infection

  • MetronidazoleDrug

    Antibiotic for complicated intra-abdominal infection

  • Amoxicillin-ClavulanateDrug

    Antibiotic for complicated intra-abdominal infection

  • SulopenemDrug

    Antibiotic for complicated intra-abdominal infection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical SuccessTime frame: Day 28 +/- 1 day

Locations

42 sites in 7 countries. Site status is shown where the registry gives one.

  • Medical Facility

    Chula Vista, California

  • Medical Facility

    Torrance, California

  • Medical Facility

    Idaho Falls, Idaho

  • Medical Facility

    Boston, Massachusetts

  • Medical Facility

    Royal Oak, Michigan

  • Medical Facility

    St Louis, Missouri

  • Medical Facility

    Butte, Montana

  • Medical Facility

    Lincoln, Nebraska

  • Medical Facility

    Omaha, Nebraska

  • Medical Facility

    Somers Point, New Jersey

  • Medical Facility

    Columbus, Ohio

  • Medical Facility

    Columbus, Ohio

  • Medical Facility

    Blagoevgrad, Bulgaria

  • Medical Facility

    Lom, Bulgaria

  • Medical Facility

    Pleven, Bulgaria

  • Medical Facility

    Plovdiv, Bulgaria

  • Medical Facility

    Plovdiv, Bulgaria

  • Medical Facility

    Rousse, Bulgaria

  • Medical Facility

    Sofia, Bulgaria

  • Medical Facility

    Varna, Bulgaria

  • Medical Facility

    Varna, Bulgaria

  • Medical Facility

    Kohtla-Järve, Estonia

  • Medical Facility

    Tallinn, Estonia

  • Medical Facility

    Tallinn, Estonia

  • Medical Facility

    Tartu, Estonia

  • Medical Facility

    Viljandi, Estonia

  • Medical Facility

    Võru, Estonia

  • Medical Facility

    Gori, Georgia

  • Medical Facility

    Kutaisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Kaposvár, Hungary

  • Medical Facility

    Pécs, Hungary

  • Medical Facility

    Veszprém, Hungary

  • Medical Facility

    Daugavpils, Latvia

  • Medical Facility

    Rēzekne, Latvia

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.